Morningstar | Acrux is a differentiated drug delivery specialist targeting global markets and licensee partners.
Acrux is an Australian drug delivery specialist focused on developing transdermal pharmaceutical products. It uses its proprietary transdermal drug delivery technology to develop new formulations of established drugs, bringing clinical and product life cycle management benefits. Lead product Axiron was marketed in a number of countries, including the United States, by former licensee partner Eli Lilly for low testosterone levels. Other commercialised products include an estradiol spray for menopause related symptoms, distributed in the U.S. by Perrigo under the brand Evamist; and Recuvyra, an FDA-approved analgesic opioid (fentanyl) transdermal solution for the control of postoperative pain associated with surgical procedures in dogs. Acrux is a Pooled Development Fund, or PDF, so shareholders are entitled to concessionary tax treatment on dividends and capital gains.Acrux is a pharmaceutical company engaged in the development and commercialization of specialty and generic transdermal and topical pharmaceuticals for global markets. Co.'s topical or transdermal pharmaceutical product portfolio can be segregated into two streams - generic pharmaceutical products and specialty pharmaceutical products.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.